Alnylam Pharmaceuticals (NASDAQ:ALNY) specializes in developing therapies based on RNA interference (RNAi), a groundbreaking approach in gene silencing that targets the root cause of diseases at the genetic level. Its operations are deeply entrenched in the discovery, development, and commercialization of RNAi therapeutics for patients with rare genetic diseases and other conditions with limited treatment options. Among its projects, Alnylam has successfully brought several drugs to market and has a rich pipeline focusing on genetic medicines, liver diseases, and cardiovascular health. The company's objective is to harness the power of RNAi to address diseases that have been historically difficult to treat through conventional methods, aiming to make significant contributions to medical science and patient care.